- Home
- SCNX vs FGEN Comparison
SCNX vs FGEN Comparison
Compare SCNX & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SCNX
- FGEN
- Stock Information
- Founded
- SCNX 2010
- FGEN 1993
- Country
- SCNX United States
- FGEN United States
- Employees
- SCNX N/A
- FGEN N/A
- Industry
- SCNX Other Pharmaceuticals
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- SCNX Health Care
- FGEN Health Care
- Exchange
- SCNX Nasdaq
- FGEN Nasdaq
- Market Cap
- SCNX 14.4M
- FGEN 33.5M
- IPO Year
- SCNX 2020
- FGEN 2014
- Fundamental
- Price
- SCNX $1.60
- FGEN $5.76
- Analyst Decision
- SCNX
- FGEN Strong Buy
- Analyst Count
- SCNX 0
- FGEN 1
- Target Price
- SCNX N/A
- FGEN $250.00
- AVG Volume (30 Days)
- SCNX 176.5K
- FGEN 60.4K
- Earning Date
- SCNX 08-10-2025
- FGEN 08-05-2025
- Dividend Yield
- SCNX N/A
- FGEN N/A
- EPS Growth
- SCNX N/A
- FGEN N/A
- EPS
- SCNX N/A
- FGEN N/A
- Revenue
- SCNX $146,901.00
- FGEN $6,996,000.00
- Revenue This Year
- SCNX N/A
- FGEN N/A
- Revenue Next Year
- SCNX N/A
- FGEN N/A
- P/E Ratio
- SCNX N/A
- FGEN N/A
- Revenue Growth
- SCNX N/A
- FGEN N/A
- 52 Week Low
- SCNX $0.69
- FGEN $4.50
- 52 Week High
- SCNX $23.77
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- SCNX N/A
- FGEN 43.29
- Support Level
- SCNX N/A
- FGEN $5.37
- Resistance Level
- SCNX N/A
- FGEN $5.73
- Average True Range (ATR)
- SCNX 0.00
- FGEN 0.41
- MACD
- SCNX 0.00
- FGEN 0.07
- Stochastic Oscillator
- SCNX 0.00
- FGEN 77.78
About SCNX Scienture Holdings Inc. Common Stock
Scienture Holdings Inc is a comprehensive health services and pharmaceutical product company. The group focused on providing value to patients and caregivers by offering novel specialty products to satisfy unmet market needs and optimize the prescription journey and patient engagement in the U.S.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.